Anticoagulation prophylaxis post-knee and hip arthroplasty is recommended but commonly used thromboprophylaxis drugs have some limitations. How does oral rivaroxaban compare to subcutaneous enoxaparin ...

TIMI-11B (Thrombolysis In Myocardial Infarction 11B) 270 was a double-blind study comparing enoxaparin (bolus followed by SC injections every 12 hours for 3 to 8 days) and IV heparin (administered for ...

A new weekly injectable drug could transform the lives of more than eight million people living with Parkinson's disease, ...

argenx SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart, at a 1000 mg dose, administered through a subcutaneous ...

Panelists discuss how transitioning patients from intravenous (IV) to subcutaneous (SubQ) therapies demands a coordinated, multidisciplinary approach—integrating clinical judgment, electronic medical ...

"We are pleased to announce the European Commission approval of the subcutaneous injection of VYVGART, which is co-formulated with our ENHANZE drug delivery technology for use in CIDP patients.

Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, ...

SE (NASDAQ:ARGX) said on Friday that it has received approval from the European Commission for its IgG Fc-antibody fragment, Vyvgart's 1000 mg dose, administered through a subcutaneous injection. This ...

The company recently announced that the European Commission approved a new subcutaneous formulation of Opdivo, developed in collaboration with Halozyme’s ENHANZE technology. This approval allows the ...